Piper Sandler Maintains Overweight on Oscar Health, Lowers Price Target to $45

Benzinga · 1d ago
Piper Sandler analyst Jessica Tassan maintains Oscar Health (NYSE:OSCR) with a Overweight and lowers the price target from $48 to $45.